Selected article for: "clinical trial and lopinavir mortality reduce"

Author: Norio Yamamoto; Shutoku Matsuyama; Tyuji Hoshino; Naoki Yamamoto
Title: Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
  • Document date: 2020_4_8
  • ID: 662pfa61_12
    Snippet: Nelfinavir showed the lowest EC 50 (1.13 µM), the highest SI (23.32), the second highest C max -EC 50 ratio (6.23), and the highest C trough -EC 50 ratio (3.43) among the tested HIV-1 protease inhibitors. These data indicate that nelfinavir is the best of nine drugs as a potential drug candidate for the treatment of COVID-19. Lopinavir showed the inferior results to nelfinavir, namely, higher EC 50 (5.73 µM), lower SI (12.99), lower C max -EC 5.....
    Document: Nelfinavir showed the lowest EC 50 (1.13 µM), the highest SI (23.32), the second highest C max -EC 50 ratio (6.23), and the highest C trough -EC 50 ratio (3.43) among the tested HIV-1 protease inhibitors. These data indicate that nelfinavir is the best of nine drugs as a potential drug candidate for the treatment of COVID-19. Lopinavir showed the inferior results to nelfinavir, namely, higher EC 50 (5.73 µM), lower SI (12.99), lower C max -EC 50 ratio (2.72), and lower C trough -EC 50 ratio (1.97) than nelfinavir. In a recent randomized, controlled, open-label trial, lopinavir-ritonavir did not significantly accelerate clinical improvement, reduce 28-day mortality, or decrease throat viral RNA amount in patients with severe COVID-19 6 . One of the reasons why the efficacy of author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • clinical improvement accelerate and open label trial: 1
    • clinical improvement and control open label trial: 1, 2, 3, 4, 5, 6
    • clinical improvement and drug candidate: 1
    • clinical improvement and mortality reduce: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical improvement and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical improvement and open label trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical improvement and protease inhibitor: 1, 2, 3, 4, 5, 6
    • control open label trial and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • control open label trial and open label trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • control open label trial and protease inhibitor: 1
    • drug candidate and mortality reduce: 1, 2, 3, 4, 5, 6, 7
    • drug candidate and open label: 1, 2, 3, 4
    • drug candidate and open label trial: 1
    • drug candidate and potential treatment drug candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • drug candidate and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • mortality reduce and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • mortality reduce and open label trial: 1, 2, 3, 4, 5, 6, 7, 8
    • mortality reduce and protease inhibitor: 1, 2
    • open label and protease inhibitor: 1, 2, 3, 4, 5